



Web: <http://www.mnmconferences.com/cancer-diagnosis-therapy-congress.html>

Theme: Advancement in Cancer diagnosis and Challenges in Organ Specific Cancer Treatment

Event Overview

MarketsnMarkets Conferences (MnM Conferences) is delighted to announce the inaugural Cancer Diagnosis & Therapy Congress to be held on September 3-4, 2015 London, UK.

The two day program will address key concerns such as cancer Immunotherapy, molecular targeted therapy, metabolomics in cancer tumour assessments & profiling, nanotechnology in cancer therapy, hormone therapy, stem cell Transplantation, surgical oncology, epigenetics, cancer genomics, cancer biomarkers, bio banking, non-invasive cancer diagnostics, organ specific cancers, cancer epidemiology and clinical trial in cancer research.

Bringing together 150 + experts from industry, research laboratories, hospitals, device and diagnostic manufacturers and academia in the arena of cancer research, the Cancer Therapy and Diagnosis Congress will provide an international platform to meet and network with experts from around the globe through scientific and industry oriented sessions, panel discussions, symposiums, workshops and vibrant exhibition area.

Major segments to be discussed:

- Advanced Cancer Detection, Diagnosis Methods and Technologies
- Novel Approaches to Cancer Therapy
- Emerging Challenges in Organ Specific Cancers Research

Why Attend?

- 25+ experts in the arena of Cancer research both from industry and academia
- 20+ focused discussions on challenges and opportunities
- 400+ minutes of networking
- One- on- One interactions with key experts in the industry
- Post event follow up providing all documentation from the meeting
- Tailor-made agenda
- World class exhibitions, symposiums, workshops

Attendee Profile

The conference aim is to gather broad range of professionals involved in cancer research including:

- Healthcare professionals
- Scientists working in cancer, Cancer clinicians and clinical scientists
- Academic researchers, students
- Medical oncologists, Hematologists, pathologists, immunologists, radiation oncologists, surgeons
- Other organ system specialists treating cancer patients
- Pharma and biotech professionals developing novel cancer therapies and diagnostics
- Representatives of pharmaceutical companies
- Device manufacturers & service providers
- Patient support teams, advocacy groups, cancer networks and survivors
- Professionals and volunteers engaged in palliative care
- Professionals, engaged in monitoring, fundraising
- Decision Makers from Government & NGOs

Confirmed Speakers



Prof. Peixuan Guo

William Farish Endowed Chair in Nanobiotechnology, Director of Nanobiotechnology Center University of Kentucky, USA



Prof. Hani Gabra

Director, Ovarian Cancer Action Research Centre, Imperial College Healthcare NHS Trust, London UK



Prof. Christopher Twelves

Deputy Director of Cancer Research UK, Clinical Centre, St James's Hospital, Leeds UK



Prof. Karim Nayernia

Co-Director & Head of Department of Stem Cell Medicine Newcastle University UK




Prof. Lesley Fallowfield

Director:(SHORE-C) Brighton & Sussex Medical School University of Sussex UK



Prof. Michael Lisanti

Director of the Breakthrough Breast Cancer Research Unit, Cancer Research UK Manchester Institute UK



Prof. Peter J. Parker

London Research Institute CRUK Lincoln's Inn Fields King's College London UK



Prof. Edward Leen

Chair of Radiology Imperial College London Hammersmith Hospital Campus UK




Prof. Robert Hawkins

Director of Medical Oncology University of Manchester and Christie Hospital, Cancer Research UK UK



Brett Wilson

CEO/ Founder Walking Miracles Inc USA



Dr. Raul Cordoba

Fundacion Jimenez Diaz University Hospital, Madrid Spain



Prof. Riccardo A. Audisio

University of Liverpool President, European Society of Surgical Oncologists & BASO UK



Prof. Stefan Gluck

Vice President Global Medical Affairs, Celgene USA



Prof. Thomas J. Vogl

Director, Department of Diagnostic and Interventional Radiology Wolfgang Goethe-University Germany



Dr. John Castle

Senior Director Bioinformatics Agenus & 4-Antibody AG, Basel Switzerland



Prof. Robert Brown

Head of Division of Cancer / Chair in Translational Oncology Imperial College London UK



Prof. Ken Mills

Chair, Experimental Haematology Centre for Cancer Research and Cell Biology, Queen's University Belfast, UK



Prof. Michelle Garrett

University of Kent General Secretary, The British Association for Cancer Research UK




Prof. Kristijan Ramadan

Associate Professor and MRC Senior Group Leader, CRUK/MRC Oxford Institute for Radiation Oncology UK



Dr. Gianni Mura

Surgical Oncologist and General Surgeon Valdarno Hospital, Arezzo Italy



William P. Chastain

Director APeX Disease Research Institute USA



Prof. Pedro Rondot Radío, MD

University of Buenos Aires Army Social Security Argentina




Prof. Kathryn Ball
Chair in Biochemistry and Cell Signalling
Edinburgh Cancer Research Centre
UK



Prof. Marek K. Janiak
Head, Dept. of Radiobiology and Radiation Protection, Military Institute of Hygiene and Epidemiology
Poland



Hassan Z Malik
University Hospital Aintree
Honorary Secretary, British Association of Surgical Oncology
UK



Dr. Michela Garofalo
Group Leader, Transcriptional Networks in Lung Cancer
CRUK, The University of Manchester
UK




Dr. Claus Jorgensen
Group Leader, Systems Oncology
Cancer Research UK Manchester Institute, The University of Manchester
UK



Prof. Arnie Purushotham
Director of King's Health Partners Integrated Cancer Centre, Vice-Dean International, King's College London
UK



Dr. Francois Lassailly
Head, In Vivo Imaging
London Research Institute
Cancer Research UK
UK



Prof. Jacqui Shaw
Professor of Translational Cancer Genetics, Department of Cancer Studies, University of Leicester
UK



Dr. James M Flanagan
Non-Clinical Senior Lecturer
Department of Surgery & Cancer
Imperial College London
UK



Prof. Jude Fitzgibbon
Professor of Personalised Cancer Medicine, Barts Cancer Institute
Queen Mary University of London
UK



Dr. Dana Flavin-Konig
Executive Director
Foundation for Collaborative Medicine and Research
USA




Dr. Esther Baena
Group Leader, Cancer Research UK
Manchester Institute
The University of Manchester
UK



Dr. Alan Prem Kumar
Cancer Science Institute of Singapore, School of Biomedical Sciences, Curtin University
Australia



Dr. Christos Christopoulos
Consultant, Radiation Oncologist
Metropolitan Hospital
Greece



Dr. Ilaria Malanchi
Group Leader, Tumour Host Interaction Lab, Cancer Research UK
London Research Institute
UK



Prof. Pedro Estrela
Associate Professor
Department of Electronic & Electrical Engineering, University of Bath
UK




Dr. John Brognard
Group Leader, Signalling Networks in Cancer, CRUK, The University of Manchester
UK



Dr. Fernando Calvo
Team Leader, Division of Cancer Biology, The Institute of Cancer Research
UK



Prof. Feng-Chi Ho
President, Global Oncology Academy, Visiting Proffessor
Guangzhou East Cancer Hospital
China



Dr. Alan G. Ramsay^[Reserved]
Team Leader, Lymphoma Immunology, Department of Hemato-Oncology, King's College London
UK

Stream-1 (Cancer Diagnosis)

Advanced Cancer Diagnosis Methods and Technologies

- Next-gen sequencing for diagnosis and monitoring of cancers
- Biomarkers in cancer diagnosis and prognosis
- Clinical proteomics & metabolomics assays for cancer biomarkers discovery
- Role of Biobank establishment for cancer research & treatment
- Image-guided photodynamic therapy of oral leukoplakia
- Advancements in CT Scan, MRI Scan, Mammograms, Radiography etc.
- High resolution microendoscopy , CryoPen, cryotherapy device
- Non-invasive cancer diagnostics: MR guided Focused Ultrasound Surgery
- Camera pill technology & 3D printing technology in cancer detection
- Portable computer-aided detection and diagnostic (CADD) tools

Emerging Challenges in Organ Specific Cancers Research

- Breast, Prostate, Lung, Pancreatic, ovary and other organ specific cancers
- Cancer Epigenetics, MicroRNAs and Long Noncoding RNAs
- Novel medical practices in clinical oncology
- Clinical trials, regulatory affairs and ethical challenges
- Challenges in healthcare IT : Cancer Databases, Bioinformatics in cancer research, clinical and scientific data management
- Cancer Epidemiology, control and palliative care
- pathogens as origins or accompaniment in cancers

Stream-2 (Cancer Therapy)

Novel Approaches to Cancer Therapy

- Cancer Immunotherapy
- Molecular Targeted Cancer Therapy and precision medicines
- Metabolomics approach towards cancer therapy
- Nanotechnology in cancer therapy
- Genomic tumor assessment & tumor molecular profiling
- Hormone therapies & Gene expression modulators
- Small Oligonucleotides therapy
- New Therapies with pleiotropic activity (including HDAC, Bromodomain modulators, HSP90, IMiDs, Proteasome)
- Hematopoietic Cell, Bone marrow, stem cell transplantation to treat cancer
- Stem Cell Transplantation for Cancer treatment
 - Hematopoietic Cell, Bone marrow and stem cell transplantation
 - Cancer Stem Cell Markers
 - Mass stem cells production technologies

Contact Us

Asia:

UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, MH 411013
India
Tel. +91 20 6075 6011

United Kingdom:

The Kidlington Centre
Kidlington, Oxfordshire
OX5 2DL
United Kingdom
Tel. +44 (0)1865-842-976

For Speaker, Delegate & Poster opportunity/ Suggestions:

Rajesh Guru

Email: rajesh.guru@mnmcconferences.com
Mob: +91-8796 554 246 / Tel: +91 20 67256006

For worldwide media partner/ collaboration:

Namrata Naikpawar

Email: namrata.naikpawar@mnmcconferences.com
Mob: +91-8796 554 246 / Tel: +91 20 60756011

For Sponsorship/ Exhibition:

Steve Hambrook

Email: steve.h@mnmcconferences.com



<http://www.mnmcconferences.com/cancer-diagnosis-therapy-congress.html>



rajesh.guru@mnmcconferences.com



India: +91 20 6075 6011 (O)/ +91-8796 554 246 (M)
UK: +44 1865 842 976

